Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Renew reports in-line interim results, raises dividend

(Sharecast News) - Engineering firm Renew has delivered interim results in line with revised expectations following a profit warning in January, with the company raising its dividend despite flat profits in the first half. The company, which provides engineering services for critical UK infrastructure, experienced an "unprecedented delay and deferment within certain Rail renewals programmes" during the six months to 31 March, meaning adjusted operating profits were down 1% on the previous year at £32m.

Nevertheless, group revenues were up 13% year-on-year at £569.3m, which Renew said was "driven by our diversified end market exposure and the consistent demand for our mission-critical services".

Meanwhile, the group's order book continued to hit new record levels at £908m by the period-end, up from £831m a year earlier.

The interim dividend was increased 5.4% to 6.7p per share.

"Renew's foundations have never been stronger in terms of the breadth of our service offering, our secured new and existing frameworks and our corresponding record order book," said chief executive Paul Scott.

"As we enter the second half of the year, we are well placed to deliver on our ambitious long-term growth strategy. As a result, the group remains confident in its ability to deliver against revised full-year expectations, which are ahead of the prior year."

Shares were up 2.1% at 811.4p in early deals on Tuesday.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.